Xiaowei Chang
Directeur/Bestuurslid bij AMBRX INC
Profiel
Xiaowei Chang is currently the Director at Ambrx, Inc. and the Managing Director-Healthcare Investment at Hopu Investments Co. Ltd.
He previously served as an Independent Director at Ambrx Biopharma Cayman, Inc. from 2015 to 2023 and as a Senior Associate at China International Capital Corp.
Ltd.
(Private Equity) from 2011 to 2014.
Mr. Chang received his undergraduate and graduate degrees from Tsinghua University.
Actieve functies van Xiaowei Chang
| Bedrijven | Functie | Begin |
|---|---|---|
| AMBRX INC | Directeur/Bestuurslid | 01-06-2015 |
Hopu Investments Co. Ltd.
 Hopu Investments Co. Ltd. Financial ConglomeratesFinance Hopu Investments Co. Ltd. functions as an investment holding Caymanian company. | Corporate Officer/Principal | 01-01-2014 |
Eerdere bekende functies van Xiaowei Chang
| Bedrijven | Functie | Einde |
|---|---|---|
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Directeur/Bestuurslid | 06-10-2023 |
| China International Capital Corp. Ltd. (Private Equity) | Corporate Officer/Principal | 01-01-2014 |
Opleiding van Xiaowei Chang
| Tsinghua University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Hopu Investments Co. Ltd.
Hopu Investments Co. Ltd. Financial ConglomeratesFinance Hopu Investments Co. Ltd. functions as an investment holding Caymanian company. | Finance |
| China International Capital Corp. Ltd. (Private Equity) | Finance |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
